[Concurrent weekly nedaplatin-based radiotherapy for high risk, recurrent and advanced cervical cancer].
[Concurrent weekly nedaplatin-based radiotherapy for high risk, recurrent and advanced cervical cancer].
复制标题
[针对高危、复发和晚期宫颈癌每周同时进行奈达铂放疗]。
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Yoshiaki Tanaka
中科院分区：
文献类型：
--
作者：
T. Idei;H. Sakamoto;Y. Nakajima;Y. Hiraiwa;Noriko Takami;F. Chishima;K. Ohtani;M. Nagaishi;Tatsuo Yamamoto;J. Kawamori;K. Himi;Yoshiaki Tanaka
在日本，晚期宫颈癌主要采用外照射和近距离放射治疗相结合的治疗方法。最近的研究表明，同时使用顺铂和放射治疗比仅放射治疗具有更好的疾病控制效果。我们对晚期或复发性宫颈癌患者 (n = 6) 进行了一项 I 期试点研究，每周同时使用奈达铂 (30 mg/m2) 和序贯外照射和近距离放射治疗。所有患者均完成治疗，无严重并发症。五名患者获得完全缓解，一名患者获得部分缓解。奈达铂一次给药后的平均 AUC 为 5.0 微克/ml.hr。治疗指数为2。我们得出的结论是，日本女性对每周一次奈达铂和放射治疗的耐受性良好，并且很可能是对于选定的晚期或复发性宫颈癌病例的一种极好的治疗方式。
Advanced cervical cancer has been predominantly treated with a combination of external beam and brachytherapy in Japan. Recent studies suggest concurrent use of cisplatin and radiation treatment has superior disease control to radiation only treatment. We have conducted a phase I pilot study of concurrent use of weekly nedaplatin (30 mg/m2) and sequential external beam and brachytherapy in advanced stage or recurrent uterine cervical cancer patients (n = 6). All patients completed the treatment without serious complications. Five patients had complete responses and one a partial response. The average AUC of nedaplatin after one administration was 5.0 micrograms/ml.hr. The therapeutic index was 2. We concluded that concurrent use of weekly nedaplatin and radiation is well tolerated by Japanese women, and may well be an excellent therapeutic modality for selected cases of advanced or recurrent cervical cancer.